The article reviews potential biomarkers for the early diagnosis and prediction of cardiac cachexia in chronic heart failure.
Biomarkers for cardiac cachexia remain investigational; leaves open prospective validation before any clinical role in heart failure.
Regardless current achievements of medicine, chronic heart failure (CHF) is still the leading cause of cardiovascular morbidity and mortality. A special cohort in CHF mortality are patients with progressive body mass loss. Recently the assessment of cachexia is restricted only with the tests revealing present atrophy, but not to predict it. Therefore, of the most significant investigation directions is search for reliable biomarkers of early diagnostics and efficacy assessment. The article focuses on the main biomarkers having potential prediction value and recommended for cardiac cachexia assessment.
No takes yet. Share an insight, caveat, or question.
Дробышева et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: